News

Regulatory and public health agencies in the US provide clear guidance on what products may be used in outbreaks of emerging pathogens.

Seqirus announced today that the US Food and Drug Administration (FDA) has approved Fluad Quadrivalent, touted as the first and only adjuvanted quadrivalent influenza vaccine, developed to help protect adults 65 years and older against seasonal influenza.

New technologies have emerged in EVS practices that infection preventionists can help review before a facility decides to implement.

Symptoms include difficult breathing, fever in a baby who is younger than 2 months, a fever that lasts for 3 days or longer, or fever that doesn’t respond to fever-fighting medication.

On average, copper beds harbored 94% fewer bacteria than conventional beds.

Alma Jackson, PhD, RN, COHN-S, discusses how to overcome this occupational hazard.

Netherlands study details ESBL-producing Enterobacteriaceae strategy.

Disposable designs will improve patient safety

Bug of the Month helps educate readers about existing and emerging pathogens of clinical importance in healthcare facilities today. Each column explores the Bug of the Month's etiology, the infections it can cause, the modes of transmission, and ways to fight its spread.

First impressions are important -- they can set the stage for the entire course of a relationship. The same is true for the impressions the cells of our immune system form when they first meet a new bacterium.

The National Institutes of Health and partners today announced plans to conduct a Phase 3 HIV vaccine efficacy trial at multiple clinical research sites in North America, South America and Europe. The trial, called HPX3002/HVTN 706 or Mosaico, will assess whether an investigational vaccine regimen designed to induce immune responses against a variety of global HIV strains can safely and effectively prevent HIV acquisition among men who have sex with men and transgender people.